Axovant to Present New Results on Intepirdine and Nelotanserin Research Programs

Axovant to Present New Results on Intepirdine and Nelotanserin Research Programs
New results from its intepirdine (RVT-101) and nelotanserin research programs on Alzheimer’s disease (AD) and Lewy body dementia will be shared soon, Axovant Sciences announced. The data will be presented at the 2017 Alzheimer's Association International Conference (AAIC) in London  July 16-20. Intepirdine is a selective antagonist of the 5HT6 receptor. This effect leads to the release of acetylcholine, an essential neurotransmitter that plays a key role in cognition, and whose levels are decreased in dementia. Intepirdine is orally administered and provided in combination with Aricept (donepezil), a drug approved by the U.S. Food and Drug Administration to prevent the degradation of acetylcholine by the enzyme cholinesterase. By increasing the concentration of acetylcholine this combination therapy aims to improve the cognition and function of patients with mild-to-moderate AD. The drug is undergoing the Phase 3 international MINDSET study (NCT02585934), which evaluates its safety, tolerability, and effectiveness in patients with mild-to-moderate AD. Intepirdine also is undergoing the Phase 2b study HEADWAY-DLB (NCT02669433), to evaluate its safety, tolerability, and effectiveness in patients with dementia with Lewy bodies. In addition, the effect of intepirdine on gait and balance in patients with dementia is under evaluation in a Phase 2 trial. The study aims to further explore the previously observed reduced rate of falls in patients treated with intepirdine in a study enrolling 684 patien
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *